Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Most labs testing children for cardiac troponin lack pediatric reference ranges, survey finds (opens in a new tab)

medicalxpress.com · 2026-10-10

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One claim goes further than the study. 3 other points were not covered by the paper.

  • 2 supported
  • 1 overstated
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

One claim overstates the study. Two of six check out. Three claims the study doesn't address.

  • 2 supported
  • 1 overstated
  • 3 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6OverstatedMost laboratories testing children for cardiac troponin rely on adult reference intervals rather than child-specific ones.View evidenceHide evidence

As stated65.5% of in-house testing laboratories lacked child-specific reference intervals

Why this verdict

The paper supports the core finding that, among respondents offering in-house cTn testing, 65.5% lacked pediatric-specific reference intervals. The story’s headline framing says “most laboratories testing children” rely on adult reference intervals, which generalizes beyond the surveyed/responding in-house-testing subset and states adult-interval use more directly than the abstract evidence, which says they lacked pediatric-specific intervals. The headline therefore outruns the more conditional survey evidence.

1

Study evidence

Among sites reporting in-house cardiac troponin testing, 65.5% lacked pediatric-specific reference intervals.65.5%

“Among the 58.4 % who reported offering in-house cTn testing, 65.5 % lacked pediatric-specific reference intervals.”
Claim 2 of 6Not coveredA new global survey examined how pediatric cardiac troponin testing is being handled around the world and was published in Clinical Chemistry and Laboratory Medicine.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that this was an IFCC international electronic survey on pediatric cardiac troponin testing, with 330 eligible responses from 48 countries. However, the supplied paper profile does not verify the publication venue, Clinical Chemistry and Laboratory Medicine, so that part of the claim is not verifiable from the provided abstract-depth evidence.

1

Study evidence

Proportion of respondents offering in-house pediatric cardiac troponin testing.58.4%

“The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Committee on Emerging Technologies in Pediatric Laboratory Medicine (C-ETPLM) conducted an electronic survey in 2025.”
Claim 3 of 6Not coveredThe article says troponin testing is used in children for a range of conditions including heart infections, Kawasaki disease, and cancer-treatment-related heart damage, and that one generic normal range may not be sufficient across these settings.View evidenceHide evidence

Why this verdict

The abstract-level profile supports only the general point that clinicians reported a broad range of pediatric cTn indications and that standardized indications and validated pediatric reference intervals are lacking. It does not verify the specific listed conditions—heart infections, Kawasaki disease, or cancer-treatment-related cardiac damage—or the stronger interpretation that condition-specific benchmarks are needed rather than a generic reference range.

1

Study evidence

Clinicians reported a broad range of indications for cTn testing in pediatric patients.

“Clinicians indicated a broad range of indications for cTn testing in pediatric patients.”
Claim 4 of 6Not coveredDr. Lianna G. Kyriakopoulou is quoted as calling for coordinated global action to develop pediatric reference intervals, strengthen clinical guidance, and ensure accurate, meaningful, and equitable results for children.View evidenceHide evidence

Why this verdict

The paper profile supports the general theme that lack of validated pediatric reference intervals, limited clinical guidance, and non-standardized indications are major barriers. However, the named quotation from Dr. Lianna G. Kyriakopoulou and its exact call for coordinated global action, equity, and meaningful results are not present in the supplied abstract-depth evidence.

1

Study evidence

Clinicians reported a broad range of indications for cTn testing in pediatric patients.

“Clinicians indicated a broad range of indications for cTn testing in pediatric patients.”
Claim 5 of 6SupportedAmong eligible respondents, 58.5% reported offering cardiac troponin testing in-house, and 65.5% of those lacked child-specific reference intervals.View evidenceHide evidence

As stated58.5% and 65.5%

Why this verdict

The abstract profile reports that 58.4% of eligible respondents offered in-house cTn testing and that, among those, 65.5% lacked pediatric-specific reference intervals. The story’s 58.5% differs by 0.1 percentage point from the supplied profile, but the substantive finding and conditional denominator are aligned.

1

Study evidence

Proportion of respondents offering in-house pediatric cardiac troponin testing.58.4%

“The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Committee on Emerging Technologies in Pediatric Laboratory Medicine (C-ETPLM) conducted an electronic survey in 2025.”
2

Study evidence

Among sites reporting in-house cardiac troponin testing, 65.5% lacked pediatric-specific reference intervals.65.5%

“Among the 58.4 % who reported offering in-house cTn testing, 65.5 % lacked pediatric-specific reference intervals.”
Claim 6 of 6SupportedSome clinics have set child-specific troponin benchmarks, but the article says practices are inconsistent and there is no agreement on how to derive the correct reference interval.View evidenceHide evidence

Why this verdict

The paper profile states that among respondents providing pediatric reference intervals, there was considerable variability in derivation methods, numerical limits, and sex-specific stratification. It also identifies lack of validated pediatric reference intervals and guidance as a major limitation. This supports the story’s claim that some sites have child-specific benchmarks but practices are inconsistent and derivation is not standardized.

1

Study evidence

Among sites reporting in-house cardiac troponin testing, 65.5% lacked pediatric-specific reference intervals.65.5%

“Among the 58.4 % who reported offering in-house cTn testing, 65.5 % lacked pediatric-specific reference intervals.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Operational findings: high-sensitivity cTn assays were widely available and at least 71% of respondents reported turnaround times under 2 hours.

    This operational-service finding is in the paper profile but is not covered in the story summary or claims.

    From Electronic cross-sectional survey

  • Key limitation: clinician respondents were only 5.8% of the sample, limiting generalizability of clinician-reported indications and needs.

    The story discusses clinical uses and need for guidance but does not mention that clinician perspectives were a small minority of respondents, an interpretation-relevant limitation for claims about clinical indications.

    From Electronic cross-sectional survey; Electronic cross-sectional survey

  • Key limitation: representativeness is uncertain because the abstract does not provide the total invited population, response rate, or weighting/adjustment procedures; responses came through IFCC member networks.

    The story frames the survey globally, but its caveats do not mention sampling-frame or representativeness constraints that affect how far the percentages can be generalized to laboratories worldwide.

    From Electronic cross-sectional survey; Electronic cross-sectional survey (IFCC C-ETPLM); Electronic cross-sectional survey

5 things the story did carry across
  • International IFCC electronic survey design and sample: 19-question survey distributed through IFCC networks in 2025, with 330 eligible responses from 48 countries.
  • In-house pediatric cardiac troponin testing availability: 58.4% of eligible respondents reported offering in-house testing.
  • Reference interval gap: among respondents offering in-house cTn testing, 65.5% lacked pediatric-specific reference intervals.
  • Heterogeneity among sites with pediatric reference intervals: derivation methods, numerical limits, and sex-specific stratification varied considerably.
  • Clinician-reported indications were broad, and respondents identified lack of validated pediatric reference intervals, limited clinical guidelines, and non-standardized testing indications as major barriers.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataMap global availability, utilization patterns, and operational characteristics (assay type, in-house vs send-out, turnaround times) of pediatric cardiac troponin testing across laboratories/clinical services via an IFCC survey.Electronic cross-sectional surveyExpand

In plain English

International cross-sectional electronic survey (IFCC C-ETPLM, 2025) describing global availability, assay characteristics, turnaround times, provision of pediatric reference intervals, clinician-reported indications, and perceived barriers to pediatric cardiac troponin (cTn) testing based on 330 eligible responses from 48 countries.

Key findings

  • Proportion of respondents offering in-house pediatric cardiac troponin testing.58.4%
  • Among respondents offering in-house testing, majority did not provide pediatric-specific reference intervals.65.5% (lacked pediatric-specific reference intervals among in-house providers)
“The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Committee on Emerging Technologies in Pediatric Laboratory Medicine (C-ETPLM) conducted an electronic survey in 2025.”
What this piece can’t prove
  • Survey-derived data are self-reported and descriptive; abstract does not present inferential analyses.
  • Clinician perspectives were a small minority (5.8%) of respondents, which may limit generalizability of clinician-reported indications and needs.

1 further detail could not be confirmed from the summary.

2secondary dataCharacterize the presence, derivation approaches, and variability of pediatric-specific reference intervals for cardiac troponin among sites reporting them.Electronic cross-sectional survey (IFCC C-ETPLM)Expand

In plain English

In a 2025 IFCC electronic survey (330 eligible responses), among sites reporting in-house cardiac troponin (cTn) testing, 65.5% lacked pediatric-specific reference intervals; among respondents who did provide pediatric intervals, the survey reported considerable heterogeneity in how intervals were derived, the numerical limits used, and whether intervals were sex-stratified.

Key findings

  • Among sites reporting in-house cardiac troponin testing, 65.5% lacked pediatric-specific reference intervals.65.5%
  • Among respondents who provided pediatric-specific reference intervals, there was considerable variability in how intervals were derived, the numerical limits reported, and whether intervals were sex-specific.
“Among the 58.4 % who reported offering in-house cTn testing, 65.5 % lacked pediatric-specific reference intervals.”
What this piece can’t prove
  • Findings derive from an electronic cross-sectional survey of IFCC members and their networks; responses are self-reported.
  • Respondent mix was heavily weighted toward laboratory specialists (clinicians 5.8%), which may affect representativeness of clinical practice perspectives.
  • Abstract reports qualitative summary of heterogeneity without detailed numerical breakdown of derivation methods or interval values.
3secondary dataIdentify perceived challenges/limitations and clinical indication patterns for pediatric cardiac troponin testing as reported by laboratory professionals and clinicians.Electronic cross-sectional surveyExpand

In plain English

Survey responses indicated clinicians report a broad range of indications for pediatric cardiac troponin (cTn) testing. Both clinicians and laboratory professionals identified the absence of validated pediatric reference intervals, lack of clear clinical guidelines, and non-standardized testing indications as major barriers to appropriate use. Among respondents offering in-house cTn testing, most (65.5%) reported no pediatric-specific reference intervals, and where intervals were provided their derivation, numerical limits, and sex-specific stratification varied considerably. Clinicians made up a small proportion of respondents (5.8%).

Key findings

  • Clinicians reported a broad range of indications for cTn testing in pediatric patients.
  • Both clinicians and laboratory professionals consistently identified the lack of validated pediatric reference intervals, absence of clear clinical guidelines, and non-standardized testing indications as major limitations to pediatric cTn use.
“Clinicians indicated a broad range of indications for cTn testing in pediatric patients.”
What this piece can’t prove
  • Clinician respondents comprised a small proportion of the sample (5.8%), limiting representation of clinician perspectives.
  • Findings are based on an electronic survey distributed to IFCC members and networks over one month; abstract provides limited detail on survey instrument content and response representativeness.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

Candidate

Reference Interval Validation of High-Sensitivity Cardiac Troponin T Assay in Thai Population

Case Medical Research · 2019 · Crossref

Source (opens in a new tab)
Candidate

Canadian Laboratory Initiative on Pediatric Reference Interval Database (CALIPER): Pediatric reference intervals for an integrated clinical chemistry and immunoassay analyzer, Abbott ARCHITECT ci8200

Clinical Biochemistry · 2009 · Crossref

Tessa (opens in a new tab)Source (opens in a new tab)

And 9 more candidates considered.